Revo Foods Launches 3D‑printed Mycoprotein Chicken Fillet Across Europe

Why It Matters

Revo Foods’ El Pollo demonstrates how advanced fermentation and 3D‑printing can produce protein at scale with a fraction of the land, water and greenhouse‑gas emissions associated with conventional poultry. By delivering a high‑fibre, low‑fat product that meets European nutritional guidelines, the launch addresses two persistent public‑health challenges: protein overconsumption and fibre deficiency. If consumers embrace the product, it could accelerate the shift toward more sustainable protein sources, prompting traditional meat producers to invest in alternative technologies. The branding shift—from “alternative” to “inspired by chicken”—also signals a broader industry trend of moving away from direct imitation toward highlighting unique nutritional attributes. This could reshape consumer expectations, encouraging a focus on health benefits rather than taste parity, and may influence regulatory discussions around labeling and marketing of novel foods in the EU.

Key Takeaways

• Revo Foods launches El Pollo, a 3D‑printed whole‑cut mycoprotein chicken fillet, in Austria, Germany and Italy next month.
• The fillet provides 13 g protein and 8 g fibre per 100 g, earning a Nutri‑Score A.
• Production capacity increased to 20 tonnes per month – a ten‑fold rise from early‑2025.
• Mycoprotein can double its biomass every five hours, making it one of the most efficient protein sources.
• Founder Robin Simsa repositions the product as a health‑first offering rather than a direct chicken substitute.

Pulse Analysis

Revo Foods’ entry into the European market with a 3D‑printed mycoprotein chicken fillet marks a pivotal moment for food‑tech scalability. Historically, plant‑based meat startups have struggled to match the texture and juiciness of animal proteins at industrial volumes. By integrating fat and fibre through computer‑guided extrusion, Revo has closed that gap, delivering a product that satisfies both sensory and nutritional criteria. The ten‑fold capacity boost to 20 tonnes per month suggests the technology has moved beyond pilot‑scale proof‑of‑concept, positioning the company to compete with established meat processors on price and supply reliability.

The strategic decision to avoid the “alternative” label reflects a nuanced understanding of consumer psychology. Early plant‑based products often suffered from direct comparison fatigue, where shoppers dismissed them for not perfectly replicating meat. By framing El Pollo as a distinct, health‑focused protein, Revo sidesteps that trap, potentially expanding its appeal to health‑conscious consumers who may not be seeking a meat replica but rather a nutritious, sustainable option. This approach could set a new marketing template for the sector, prompting rivals to emphasize unique benefits over mimicry.

Looking ahead, the real test will be market adoption and regulatory acceptance. The EU’s novel food framework demands rigorous safety assessments, and any delay could stall distribution. Moreover, price parity with conventional chicken will be essential for mass adoption. If Revo can achieve competitive pricing while maintaining its low‑waste, high‑fiber profile, it could catalyze a broader shift toward 3D‑printed mycoprotein across other protein categories, reshaping the European protein landscape for the next decade.